FDA Guidance Policy Could Be Hurt By Ruling On Animal Drug Compounding
Executive Summary
A recent court ruling on the compounding of animal drugs has grabbed the attention of pharma lawyers, who say it could have ramifications for other FDA policies and provide ammunition for those challenging the agency’s use of guidance documents.
You may also be interested in...
Contamination, Mix-Ups Drive Up Drug Recall Totals for 2012
Injectables eclipsed oral solids as 2012 generated the fourth-most recalls ever. Contamination played a major role, particularly in generating several massive recalls at compounding pharmacies, while there were also contraceptive packaging snafus, problems in confronting tablet mix-ups and other issues that generated drug recalls last year.
FDA’s Compounding Oversight: What Price Safety?
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.
FDA’s Guidance Document To-Do List Grows
Since releasing its annual guidance agenda in December, FDA has added a number of guidances to its development agenda.